Gene expression profile in peripheral blood cells of patients with COVID-19

: The clinical course of


Title of the Presentation Introduction
Coronavirus SARS-CoV-2 is the etiologic agent for COVID-19, a disease from which over 1180,000 persons have died in the past 10 months.The clinical course of COVID-19 varies from mild symptoms to acute respiratory distress syndrome, hyperinflammation, and coagulation disorder.Patients with COVID19 have a higher risk of developing blood clots (thrombosis) mainly in their lungs which is associated with higher death.In ~70% of COVID-19 patients, who died had disseminated intravascular coagulation.The blood clots can be in both venous and arterial circulations, clots in small blood vessels.Endothelium plays a key role in the pathogenesis of coagulation disorders in infectious diseases and is important for the initiation and regulation of haemostatic.Although direct interactions between the infectious agent and the endothelial cells occur, cytokines-also endothelialderived-are believed to be important mediators in this process.

Introduction
Samples were normalized to TBP as a reference control.The Mann-Whitney U test was used to assess statistical differences in gene mRNA level values.

Schematic representation of the gene expression analysis
Whole blood samples were collected from patients with acute COVID-19 infection (n=19) and healthy volunteers (n=20).The gene expression of PBCs was determined by RT-qPCR.

** ns
The mRNA level of pro-oxidation genes in PBCs of the COVID-19-infected patients.**P˂0.01 vs. Control; ns, non significant vs. Control.

Results and discussion
Expression of the IL8, IL10, IL12, TNFα, CD80, OAS1, OAS3, RNASEL, MX1, EIF2AK2, F5, F10, ARG2 was increased in the PBCs of COVID-19-infected patients compared to the healthy sample.These genes can be used as genetic markers for early detection of hyperinflammation and coagulation in patients with acute COVID-19 and evaluation of efficiency treatment of this disease.